A synthetic peptide composed of alternating L- and D-amino acid residues has been recently shown to inhibit aggregation and reduce toxic effects in neuroblastoma cells, of the beta-amyloid peptide, Aβ, implicated in Alzheimer’s disease. In contrast, a “twin” peptide with the same sequence, but with all L-amino acid residues, had no inhibitory effect on amyloidogenesis or toxicity of Aβ.
For more please download PDF file.
Contributed by Susan J. Tzotzos
Susan Tzotzos works for the Vienna-based biotech company Apeptico Forschung & Entwicklung GmbH, where she designs therapeutic peptides, oversees their synthesis and follows up their application in clinical trials. Susan also manages various research collaborations with university departments carrying out projects investigating the mode of action of Apeptico’s therapeutic peptides.